Navigation Links
Nanomedicines promise fewer side effects in treating cancer
Date:6/7/2012

A new generation of cancer treatments based on nanotechnology is making its way out of the laboratory and into the clinic with the promise of targeting cancer cells while steering clear of healthy tissue, according to the current edition of Chemical & Engineering News (C&EN). C&EN is the weekly newsmagazine of the American Chemical Society (ACS), the world's largest scientific society.

In the cover story, C&EN Senior Editor Bethany Halford explains that today's anti-cancer medications impact healthy tissue in the process of killing cancer cells. Patients thus may experience side effects, such as nausea and vomiting, that in some instances can be so severe that patients decline further treatment. New nanomedicine cancer treatments promise to focus on diseased tissue while leaving healthy parts of the body unscathed, reducing the severity of side effects.

The article explains how a new generation of nanoparticle-based medications bring anti-cancer drugs directly to the tumor. Because of their ultra-small size, particles of these drugs can slip through tiny passages in the blood vessels that nourish tumors, get inside tumors and even individual cancer cells, and do their work with precision. The article describes nanomedicines that already are in clinical trials with cancer patients and others that are moving in that direction.


'/>"/>
Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society
Source:Eurekalert

Page: 1

Related medicine news :

1. Normalizing tumor blood vessels improves delivery of only the smallest nanomedicines
2. Antioxidant shows promise as treatment for certain features of autism, Stanford study finds
3. New TB test promises to be cheap and fast
4. In Rat Study, Eye Device Shows Promise for Restoring Sight
5. New Weight-Loss Drug Shows Promise in Trial
6. New Drug Shows Promise for Myeloma Patients
7. Detecting malaria early to save lives: New optical technique promises rapid and accurate diagnosis
8. New Method to Reveal Alzheimers Marker Shows Promise
9. Brain Tumor Vaccine Shows Promise in Early Trial
10. Mechanical tissue resuscitation technology shows promise
11. Experimental Pill for Multiple Sclerosis Shows Promise
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... ... The Hong Kong Polytechnic University (PolyU) launched today the University Research Facility ... Hong Kong to support teaching, learning and research. It is also the largest research ... Hong Kong. , With an area of 620 square metres and more than ...
(Date:4/21/2017)... ... 21, 2017 , ... Airway Management, the medical device manufacturer ... regarded and well renowned Asian distributor, Discovery Sleep. The agreement involves ... Mask, and will stabilize and strengthen Airway’s presence with a dedicated, reputable medical ...
(Date:4/21/2017)... CA (PRWEB) , ... April 21, 2017 , ... Providing ... not understand the estate planning process, or where to even begin. “Now more than ... if you are to properly protect yourself and your family,” said attorney Lisa Edgar ...
(Date:4/21/2017)... , ... April 21, 2017 , ... Each year, everyone ... a day to clean, plant trees and look forward to a better future. However, ... about doing something outdoors. Indoor air quality can be two to five times more ...
(Date:4/21/2017)... ... April 21, 2017 , ... Indiana ... significant bandwidth upgrade infrastructure service to Tele-Media Solutions. IFN is delivering Multi-Gigabit ... IFN’s consortium member-owners, Tele-Media Solution’s protect transport with 3GB Dual Access Internet access ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Mass. , April 20, 2017  RXi ... developing innovative therapeutics that address significant unmet medical ... data from the Company,s consumer product development program, ... at the Society for Investigative Dermatology (SID) 76 ... to advance and promote the sciences relevant to ...
(Date:4/20/2017)... 20, 2017  AbbVie (NYSE: ABBV), a global ... of chronic hepatitis C virus (HCV) infected patients ... and compensated cirrhosis (Child-Pugh A) achieved sustained virologic ... with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). ... following 12 weeks of G/P treatment without ribavirin. ...
(Date:4/20/2017)... -- Research and Markets has announced the addition ... Analysis By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, ... report to their offering. ... The Latin American pharmaceutical contract manufacturing services market is ... Low drug registration cost in Latin American countries and continuous ...
Breaking Medicine Technology: